|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.09 USD | -0.16% |
|
-0.14% | +77.65% |
| 07-31 | Health Care Down on Rotation Out of Defense - Health Care Roundup | DJ |
| 07-31 | AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition | MT |
Company Valuation: Apogee Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,342 | 2,578 | 5,094 | 10,067 | - | - |
| Change | - | 92.13% | 97.62% | 97.63% | - | - |
| Enterprise Value (EV) 1 | 946.2 | 2,057 | 4,364 | 9,088 | 9,327 | 9,340 |
| Change | - | 117.41% | 112.14% | 108.25% | 2.63% | 0.13% |
| P/E | -8.32x | -13.7x | -17.9x | -31.1x | -24x | -22x |
| PBR | - | - | 5.51x | 8.99x | 12.3x | 15.3x |
| PEG | - | 7.67x | -0.6x | -13.66x | -0.8x | -2.44x |
| Capitalization / Revenue | - | - | - | 1,107x | 805x | 177x |
| EV / Revenue | - | - | - | 1,000x | 746x | 164x |
| EV / EBITDA | - | -9.49x | -15.4x | -26.5x | -22.3x | -18.4x |
| EV / EBIT | -10.2x | -9.49x | -15.3x | -26x | -21x | -18.6x |
| EV / FCF | -12.6x | -11.9x | -18.8x | -33.1x | -26.9x | -22.4x |
| FCF Yield | -7.92% | -8.38% | -5.33% | -3.02% | -3.72% | -4.46% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -3.36 | -3.3 | -4.22 | -4.316 | -5.583 | -6.087 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 9.091 | 12.5 | 57 |
| EBITDA 1 | - | -216.7 | -284.2 | -342.9 | -419.1 | -506.9 |
| EBIT 1 | -93 | -216.9 | -285.6 | -350 | -443.7 | -502.6 |
| Net income 1 | -83.98 | -182.1 | -255.8 | -317.5 | -416.4 | -473.4 |
| Net Debt 1 | -395.5 | -520.7 | -730.2 | -979.5 | -740.2 | -727.7 |
| Reference price 2 | 27.94 | 45.30 | 75.48 | 134.09 | 134.09 | 134.09 |
| Nbr of stocks (in thousands) | 48,018 | 56,903 | 67,488 | 75,079 | - | - |
| Announcement Date | 3/5/24 | 3/3/25 | 3/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -31.07x | 999.66x | -26.5x | -.--% | 10.07B | |
| 32.83x | 5.9x | 17.55x | 0.98% | 48.53B | |
| -23.41x | 351.08x | -21.45x | -.--% | 39.87B | |
| 30.42x | 3.04x | 13.11x | -.--% | 38.68B | |
| 46.94x | 4.76x | 30.78x | -.--% | 35.13B | |
| 28.41x | 8.22x | 20.66x | 0.41% | 29.79B | |
| 32.82x | 5.37x | 24.39x | -.--% | 16.11B | |
| 22.67x | 1.99x | 8.61x | 1.17% | 13.61B | |
| 25.33x | 1.86x | 11.4x | -.--% | 12.62B | |
| Average | 18.33x | 153.54x | 8.73x | 0.28% | 27.16B | |
| Weighted average by Cap. | 21.18x | 102.35x | 10.59x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- APGE Stock
- Valuation Apogee Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
